Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Solid Tumor 1Relapsed Solid Tumors 1Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1

Interventions

Amifostine 4Filgrastim 3Cyclophosphamide 3Melphalan 2Irinotecan 2Cytarabine 2Carboplatin 2spartalizumab 1sodium thiosulfate 1sargramostim 1lometrexol 1etoposide phosphate 1Vincristine 1Temozolomide 1Sirolimus 1Procarbazine 1Phenobarbital 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Mannitol 1Lomustine 1Interleukin-2 1Idarubicin 1Genetic Therapy 1Gemcitabine 1Folic Acid 1Fibroblast Growth Factor 7 1Fecal Microbiota Transplantation 1Drug Therapy 1Deoxycytidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Drug-Related Side Effects and Adverse Reactions × Cefixime × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡